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ORIGINAL ARTICLE
Utility of the ISTH bleeding assessment tool in predicting
platelet defects in participants with suspected inherited
platelet function disorders
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Centre for Cardiovascular Sciences, Institute of Biomedical Research, College of Medical and Dental Sciences, University of Birmingham,
Edgbaston, Birmingham, UK
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in predicting platelet defects in participants with suspected inherited platelet function disorders. J Thromb Haemost 2013; 11: 1663–8.
Summary. Background: The ISTH bleeding assessment tool
(ISTH-BAT) was developed to record bleeding symptoms
and to aid diagnosis in patients with a possible bleeding
disorder. Objectives: To investigate the utility of the ISTH-
BAT in predicting functional defects in platelet activation
in participants with suspected inherited platelet function
disorders. Patients/Methods: Participants with clinical evi-
dence of excessive bleeding and suspected inherited platelet
function disorders and healthy volunteers were recruited to
the Genotyping and Phenotyping of Platelets study
(GAPP; ISRCTN 77951167). The ISTH-BAT question-
naire was applied by a trained investigator prior to lumiag-
gregometry. Results: One hundred participants were
included (79 with suspected inherited platelet function dis-
orders, and 21 healthy volunteers). The ISTH-BAT score
in participants with suspected inherited platelet function
disorders (median 12; interquartile range [IQR] 8–16) was
significantly higher than in healthy volunteers (median 0;
IQR 0–0). There was no difference between participants
with suspected inherited platelet function disorders with a
platelet defect detected by lumiaggregometry (median 11;
IQR 8–16) and those with normal platelet function
(median 12; IQR 8–14) (P > 0.05). The ISTH-BAT score
was not associated with a demonstrable platelet defect
on platelet function testing (area under the receiver operat-
ing characteristic curve = 0.501 [95% confidence inter-
val 0.372–0.630, P = 0.98] and odds ratio 1.01 [95%
confidence interval 0.93–1.09, P = 0.91]). Conclusions: The
ISTH-BAT is a powerful tool for documenting lifelong
bleeding history. However, the score obtained is not predic-
tive of the presence of a platelet defect on lumiaggregome-
try in patients with suspected inherited platelet function
disorders.
Keywords: Blood platelet disorders; Coagulation disor-
ders, inherited; Decision support techniques; Platelet
aggregation; Platelet function tests.
Introduction
Recent years have seen the development of many forms
of bleeding assessment tool (BAT) with the aim of stan-
dardizing the documentation of symptoms of excessive
bleeding in patients, allowing comparisons between
patients and the selection of patients in whom further
investigations are appropriate. The evolution and valida-
tion of these tools, along with the rapid progress in the
field, was covered in a recent comprehensive review [1].
Many of the tools developed have been specific to certain
bleeding disorders, such as von Willebrand disease [2,3],
or have been targeted at certain populations, such as chil-
dren [4–6] or women with menorrhagia [7,8]. Interna-
tional collaboration has been recognized as being
essential in the further development of these tools, owing
to the rarity of some inherited bleeding disorders.
The ISTH-BAT was developed as a tool with which to
accurately record bleeding symptoms in all hemorrhagic
disorders and to aid diagnosis in patients referred with a
possible bleeding disorder [9]. It was designed to capture
the importance of recurrent minor bleeds in addition to
more severe hemorrhage, including life-threatening epi-
sodes. It is also a potential research tool in studies that
examine patients with excessive bleeding, allowing docu-
mentation of the severity of bleeding and comparison
between patient groups across and within studies. A
recent study has shown the ISTH-BAT to be helpful in
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assessing children and parents in routine clinical practice,
and has found it to be equally discriminative as a BAT specif-
ically designed for pediatric patients with regard to the preva-
lence of an underlying bleeding disorder [10]. However, it has
not yet been validated in a large cohort of patients with sus-
pected inherited platelet function disorders.
Materials and methods
Participant selection
Participants with suspected inherited platelet function dis-
orders were recruited to the Genotyping and Phenotyping
of Platelets study (GAPP; ISRCTN 77951167) from Octo-
ber 2011 to December 2012 from UK Comprehensive Care
Haemophilia Centres, and were invited to participate in
this study if they satisfied the following criteria:
1 Abnormal bleeding symptoms compatible with a possi-
ble inherited platelet function disorder (spontaneous
mucocutaneous bleeding or abnormal bleeding at other
sites following trauma or invasive procedures). Patients
with existing diagnoses of Glanzmann’s thrombasthe-
nia, Bernard–Soulier syndrome, May–Hegglin anomaly
or Hermansky–Pudlak syndrome were excluded.
2 Platelet count within the local laboratory reference
range.
3 Results from coagulation factor tests within local labo-
ratory reference intervals (minimum panel of prothrom-
bin time, activated thromboplastin time, Clauss
fibrinogen activity, von Willebrand factor antigen level,
ristocetin cofactor activity, and factor VIII:C activity)
Laboratory testing was deferred in participants exposed
within 2 weeks to drugs known to affect platelet function.
Healthy volunteers aged ≥ 18 years were included in this
study. Participants were considered to be healthy if they had
not previously required clinical consultation or investigation
for excessive bleeding, did not require long-term medical
therapy, and had refrained from using drugs known to influ-
ence platelet function in the previous 2 weeks.
This study was approved by the National Research
Ethics Service Committee West Midlands – Edgbaston
(REC reference: 06/MRE07/36), and all participants gave
written informed consent in accordance with the Declara-
tion of Helsinki.
Assessment of bleeding history
The ISTH-BAT was used for assessment of the partici-
pants’ bleeding history. The questionnaire was applied for
patients with suspected inherited platelet function disor-
ders (from UK Comprehensive Care Haemophilia Cen-
tres) and for healthy volunteers by trained personnel who
regularly took bleeding histories for study participants.
The bleeding assessment scores were compiled prior to
platelet function testing, so that investigators were not
influenced by lumiaggregometry results when assessing
and quantifying the bleeding history. The ISTH-BAT
score can range from 0 to 56 in women and from 0 to 48
in men, based on a maximal score of 4 in 14 separate cat-
egories assessing different types of bleeding.
Assessment of platelet function
Blood was drawn by venepuncture through a 21-gauge
needle into evacuated tubes containing 3.8% sodium cit-
rate. Platelet function was assessed with light transmission
aggregometry as described previously [11]. Platelet-rich
plasma was prepared by centrifugation of whole blood at
200 9g for 20 min, and autologous platelet-poor plasma
was obtained by further centrifugation at 1000 9g for
10 min. A dual-channel Chronolog lumiaggregometer
(Model 460 VS; Chronolog, Havertown, PA, USA) was
used to measure platelet aggregation in response to: 3, 10
and 30 lM ADP; 10 and 30 lM adrenaline; 0.5 and 1 mM
arachidonic acid; 1 and 3 lg/mL collagen; 30 and 100 lM
protease-activated receptor 1-specific peptide (SFLLRN);
and 1.5 mg/mL ristocetin. ATP secretion was assessed with
the Luciferin–Luciferase reagent (Chronolume, Chrono-
log, Havertown, PA, USA) and an ATP standard solution.
Results were classified as abnormal by reference to a bank
of local healthy volunteers [11]. Platelet function testing
operators were kept blind of the ISTH-BAT score.
Statistical analyses
Normally distributed continuous variables are presented as
mean  standard deviation, non-normally distributed con-
tinuous variables as median (interquartile range [IQR]), and
categorical variables as frequencies (percentages). Variables
were analyzed for a normal distribution with the Kolmogo-
rov–Smirnov test. The association between the presence of
platelet defects as assessed by platelet function testing and
the ISTH-BAT score was determined with the non-para-
metric Kruskall–Wallis test, with Dunn’s adjustment for
multiple comparisons. To evaluate the ISTH-BAT’s ability
to discriminate between patients with and without a demon-
strable platelet defect on platelet function testing, a receiver
operating characteristic (ROC) curve analysis was per-
formed, and a simple logistic regression was used. A two-
sided P-value of < 0.05 was considered to be significant.
Analyses were performed with SPSS 14.0 for Windows (SPSS
Institute, Chicago, IL, USA) and GRAPHPAD PRISM 5 for
Windows (GraphPad Software, San Diego, CA, USA).
Results
Participant characteristics
Of the 100 participants studied, 21 were healthy volun-
teers and 79 were recruited from UK Comprehensive
Care Haemophilia Centres with suspected inherited plate-
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let function disorders. The median age of participants
with bleeding symptoms was 39 years (IQR 31–53 years),
and that of healthy volunteers was 32 years (IQR 30–
35 years). The majority of recruited participants were
female (81% of participants with bleeding symptoms, and
67% of healthy volunteers).
Association of scores with platelet function testing results
A platelet defect was found on lumiaggregometry in 52%
of participants with bleeding symptoms, in accordance
with our previously published findings [11]. The score
obtained with the ISTH-BAT in participants referred by
UK Comprehensive Care Haemophilia Centres with
bleeding symptoms (12; IQR 8–16) was significantly
higher than in healthy volunteers (0; IQR 0–0), consistent
with the clinical diagnosis of a bleeding disorder. How-
ever, there was no significant difference between partici-
pants in whom a platelet defect was detected by
lumiaggregometry (11; IQR 8–16) and those in whom
platelet function was deemed to be normal (12; IQR 8–
14) (Fig. 1). There was no association between the type
of platelet defect detected by lumiaggregometry (as
defined in our recent study [11]) and the ISTH-BAT
score, although the numbers of patients in some diagnos-
tic classification subgroups was relatively small (Fig. 2).
A ROC curve analysis was carried out to evaluate
whether the ISTH-BAT could discriminate between
patients with and without a demonstrable platelet defect
on lumiaggregometry (Fig. 3). The area under the curve
was 0.50 (95% confidence interval [CI] 0.37–0.63,
P = 0.98), demonstrating a lack of discriminative ability.
Moreover, the ISTH-BAT score was not associated with
a demonstrable platelet defect on platelet function testing
in a simple logistic regression model (odds ratio 1.01,
95% CI 0.93–1.09, P = 0.91).
Subgroup analyses were performed to examine whether
certain bleeding symptoms were predictive of the presence
of a platelet defect on lumiaggregometry. ISTH-BAT
scores for epistaxis, cutaneous bleeding, postoperative
(including post-dental work) bleeding and menorrhagia in
women were assessed (Table 1). No statistical significance
was found for any of these subgroups.
The sensitivity, specificity, positive predictive value and
negative predictive value of the ISTH-BAT in predicting
the presence of a platelet defect on lumiaggregometry was
assessed (Table 2). A cut-off value of 12 was used for the
ISTH-BAT score, as this represented the 50th centile of
ISTH-BAT score in all patients. This analysis confirmed
the absence of association between a high ISTH-BAT
score and the likelihood of having a platelet defect
(j =  0.04, 95% CI  0.26 to 0.18).
Discussion
Our findings confirm that the ISTH-BAT score is raised
in patients with clinical evidence of excessive bleeding and
a suspected platelet function disorder. We have also
shown that healthy volunteers have a low score (≤ 4), in
keeping with the absence of a history of bleeding epi-
sodes. However, the score is unable to discriminate
between patients with clinically diagnosed bleeding disor-
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Fig. 1. Association between the presence of a platelet function defect on lumiaggregometry and the ISTH bleeding assessment tool score. 95th
percentile (score of 4) calculated from healthy volunteers and represented by the horizontal dotted line. For the data points, the line represents
the median and the whiskers represent the interquartile range. Statistical analysis was performed with the non-parametric Kruskall–Wallis test,
with Dunn’s adjustment for multiple comparisons.
© 2013 International Society on Thrombosis and Haemostasis
ISTH bleeding assessment tool and platelet disorders 1665
ders subsequently shown to have a platelet defect on lu-
miaggregometry and those in whom an underlying plate-
let defect was not detected. This suggests that the ISTH-
BAT is powerful in documenting bleeding symptoms, but
that its level as such is not predictive of the likelihood of
diagnosing an inherited platelet disorder in patients with
excessive bleeding. It is possible that some patients classi-
fied as not having a platelet defect do have a mild defect
that is below the limit of sensitivity of our current testing
assays, or have a defect in other aspects of platelet func-
tion (such as procoagulant activity) that was not tested
for. Given the history of excessive bleeding in all patients,
abnormalities in other untested parts of the hemostatic
pathway may account for the clinical presentation of a
proportion of the patients in whom we did not detect a
platelet defect.
The healthy volunteer group included in this study is
small (n = 21). The 95th centile for the ISTH-BAT score
in this group is 4, although defining a more precise upper
limit of normal range for the ISTH-BAT score would
require larger studies that would ideally examine hetero-
geneous populations. In addition, the median age in the
healthy volunteer group was slightly lower than in the
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Fig. 2. Association between type of platelet function defect on lumiaggregometry and the ISTH bleeding assessment tool score. 95th percentile
(score of 4) calculated from healthy volunteers and represented by the horizontal dotted line. For the data points, the line represents the med-
ian and the whiskers represent the interquartile range. Statistical analysis was performed with the non-parametric Kruskall–Wallis test, with
Dunn’s adjustment for multiple comparisons. For a description of the types of defect, see [11]. COX, cyclooxygenase; Gi, abnormality in Gi
signalling (predominantly seen as changes in aggregation to ADP and adrenaline).
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Fig. 3. Receiver operating characteristic curve for the presence of a
platelet function defect on lumiaggregometry and the ISTH bleeding
assessment tool score. Area under the curve: 0.50 (95% confidence
interval 0.372–0.63), P = 0.98.
Table 1 Subgroup analyses for the ISTH bleeding assessment tool
score in patients with and without a platelet defect
Bleeding
symptom
Patients with platelet
defects (median,
interquartile range)
Patients without
platelet defects
(median,
interquartile range) P-value
Epistaxis 1, 0–3 1, 0–2 0.67
Cutaneous
bleeding
1, 0–2 1, 0–1 0.17
Postoperative
bleeding
(including
post-dental
work)
4, 2–6 4, 2–6 0.89
Menorrhagia 3, 1–4 3, 2–4 0.27
Symptoms assessed were epistaxis (maximum score of 4), cutaneous
bleeding (maximum score of 4), postoperative bleeding (including
post-dental work, maximum score of 8), and menorrhagia (in female
participants only, maximal score of 4). Statistical analyses were per-
formed with the non-parametric Mann–Whitney U-test.
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patient group. This may have reduced the ISTH-BAT
score in healthy volunteers, owing to fewer cumulative
challenges to the hemostatic system, such as surgery or
pregnancy and childbirth in women. Previous work has
shown that platelet aggregability slightly increases with
age [12], meaning that the aggregation ranges observed in
the healthy volunteer group may be lower than would be
expected in the patients if platelet function was normal.
However, this would have biased the results in the patient
group towards increased platelet reactivity, and therefore
should not have led to mislabeling of patients with nor-
mal responses as having a platelet defect.
The documentation of bleeding risk in mild bleeding
disorders is challenging. Mucocutaneous bleeding symp-
toms are reported in a significant proportion of the
healthy population, which makes determination of the
threshold that constitutes excessive bleeding difficult [13].
Mild bleeding disorders are prevalent in the general popu-
lation, reaching up to 1%, but both the clinical diagnosis
and laboratory characterization remain complicated [14].
The presence of a laboratory phenotype does not neces-
sarily lead to bleeding, especially in the absence of a he-
mostatic challenge, and, as a consequence, most mild
bleeding disorders, particularly inherited platelet disor-
ders, remain clinically and biochemically ill-defined
[14,15]. There is an important clinical need for an assess-
ment tool that would allow clinical characterization of
this population, in order to stratify which patients require
further investigation.
Numerous scores for bleeding assessment have been
proposed over the years (reviewed in [15] and [1]). The
strength of the ISTH-BAT is in specifically capturing the
frequency of mild bleeding symptoms, which is often
missed by traditional BATs [9]. As such, the ISTH-BAT
is particularly relevant to patients with recurrent and mild
bleeding symptoms, which constitute a key feature of
inherited platelet disorders [14,15].
There is little prior experience with this tool in mild
bleeding disorders. Using a previous version of a BAT
based on the European MCMDM-1 VWD study [3], To-
setto et al. [16] analyzed the BAT’s clinical utility in 215
patients with mild bleeding disorders. The findings sup-
ported the use of the BAT, as a low bleeding score could
reasonably exclude the presence of a mild bleeding disor-
der in an unselected population, and the utility increased
when the BAT score was used in conjunction with labora-
tory testing [16]. Our results agree with these findings, as
patients with clinical evidence of excessive bleeding in our
study did have significantly higher ISTH-BAT scores than
healthy volunteers. A further study by Bidlingmaier et al.
[10] looked at the clinical utility of the ISTH-BAT ques-
tionnaire in a routine pediatric setting. In this study on
100 children presenting with a mild bleeding diathesis, a
low ISTH-BAT score made a bleeding disorder diagnosis
unlikely, consistent with our own findings and those of
Tosetto et al. [10,16]. However, only five children were
diagnosed with a possible platelet disorder in this study,
thus reducing the generalizability to a large cohort of
patients with suspected inherited platelet function disor-
ders. Also, given that the ISTH-BAT assesses responses
to hemostatic challenges, including menorrhagia, child-
birth, dental procedures, and surgery, the applicability of
the scores obtained in children to an adult population is
uncertain, as many children will not yet have been
exposed to these challenges.
Our study is the first to report on the utility of the
ISTH-BAT in a large cohort of patients with suspected
inherited platelet function disorders. Our findings support
the use of the ISTH-BAT to document recurrent bleeding
symptoms in this population. However, the ISTH-BAT
score is not predictive of which patients have a platelet
function defect determined by laboratory investigation
with lumiaggregometry, which is the currently accepted
gold standard for assessing platelet function.
Conclusion
Assessment of symptoms with BATs is likely to become
more important in the years to come, as the laboratory
investigation of individuals with excessive bleeding
improves, and the use of BATs will allow comparison
between patient groups and treatment centers. The fact
that the ISTH-BAT documents recurrent minor bleeding
episodes is important in the assessment of individuals
with suspected inherited platelet function disorders.
Further work in this area should include international
collaborations, such as the ISTH-BAT repository [17], to
allow further validation of the ISTH-BAT and to obtain
data on its performance in other hemorrhagic disorders.
Addendum
G. Lowe and M. Lordkipanidze: led on research gover-
nance for GAPP, recruited patients to the study, applied
the ISTH-BAT, performed lumiaggregometry, analyzed
and interpreted the results, and wrote the manuscript.
Table 2 The predictive value of an ISTH bleeding assessment tool
(ISTH-BAT) score of ≥ 12 (2 9 2 analysis) in predicting the presence
of a platelet defect on lumiaggregometry
Defect
present on
lumiaggregometry
Defect
absent on
lumiaggregometry
ISTH-BAT
score of ≥ 12
20 20 Positive
predictive
value = 50%
ISTH-BAT
score of < 12
21 18 Negative
predictive
value = 54%
Sensitivity = 49% Specificity = 53%
An ISTH-BAT score of 12 represents the 50th centile in all patients
studied. Kappa statistic for concordance =  0.04 (95% confidence
interval  0.26 to 0.18), demonstrating a lack of significance.
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S. P. Watson: chairs the GAPP program, interpreted the
results, and edited the manuscript.
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